Alzheimer's Blood Biomarkers Vary by Race and Ethnicity
New 2026 research shows cognitive biomarkers in the blood may perform differently across racial and ethnic groups.
Updated on Oct. 26, 2026 in Alzheimer’s
Live Poll
Should medical diagnostic testing be adjusted to account for differences in patient race and ethnicity?
A 2026 study in JAMA Neurology found that blood-based p-tau217 levels and their link to cognitive decline vary significantly across racial and ethnic groups. Researchers analyzed data from 15,612 adults aged 55 to 80 to better understand these biomarkers.
Why it matters
Identifying variations in how biomarkers relate to cognitive health is essential for ensuring that future diagnostic tools for Alzheimer’s disease are accurate and equitable for all patient populations. This study highlights the need for diverse representation in research to avoid biases in clinical care.
This retrospective analysis of 15,612 adults from the AHEAD 3-45 cohort examined blood-based p-tau217 biomarkers across racial and ethnic groups. While higher p-tau217 levels consistently tracked with lower cognitive scores, the specific associations with amyloid PET values differed by ethnicity.
The players
JAMA Neurology
A peer-reviewed medical journal that publishes clinical research on neurological diseases and diagnostic developments.
AHEAD 3-45
A large-scale clinical research cohort focused on screening adults aged 55 to 80 for early signs of Alzheimer’s disease.
The details
The study utilized data from the AHEAD 3-45 screening cohort to assess how the protein p-tau217, a biomarker for Alzheimer’s, correlates with cognitive performance. Researchers observed that the prevalence of the APOE ε4 genetic variant—a known risk factor for Alzheimer’s—ranged from 22.2% in Asian participants to 38.6% in White participants. By comparing these markers against PACC5 cognitive scores and amyloid PET scans, the findings demonstrate that the diagnostic performance of these blood tests is influenced by a patient's genetic and ancestral background.
Timeline
The findings were published in JAMA Neurology in 2026.
Health Landscape
As blood-based diagnostic tests for Alzheimer’s move toward clinical use, establishing population-specific baselines is the next major hurdle for medical science. This study marks a necessary shift from one-size-fits-all diagnostic models to more nuanced, equitable approaches.
If you are concerned about cognitive changes, talk with your doctor about how your specific genetic and health history might influence screening results. Understanding these variations helps ensure that any diagnostic testing you undergo is interpreted accurately for your background.
The takeaway
Blood-based biomarker tests are a developing tool, but their accuracy depends on accounting for racial and ethnic differences. Always discuss the limitations and appropriateness of any neurological screening with a specialist who understands your personal health history.
Further reading
For more information on diagnostic advancements, visit the Alzheimer’s section.
Source note: This article includes information reported by Neurology Advisor.
Live Poll
Should medical diagnostic testing be adjusted to account for differences in patient race and ethnicity?
